Allogeneic stem cell transplantation (SCT) using reducedintensity conditioning (RIC) has potential to be a promising treatment of aggressive chronic lymphocytic leukemia (CLL). Since available clinical data obtained with this novel approach are very limited, we have performed a survey on this issue. Data of 77 patients were collected from 29 European Group for Blood and Marrow Transplantation centers. Median age was 54 (30-66) years, and the median number of previous chemotherapy regimens was 3 (0-8). HLA-identical sibling donors were used in 81% of the cases. Moderate conditioning regimens (mainly low-dose total body irradiation (TBI) or fludarabine-cyclophosphamide combinations) were administered to 56% of the patients, whereas the remainder received more intense conditioning consisting of fludarabine-busulfan or high-dose melphalan combinations. In 40% of the patients, in vivo T-cell depletion (TCD) with anti-thymocyte globulin or CAMPATH-1H was part of the conditioning regimen. Cumulative treatmentrelated mortality (TRM) was 18% (95% CI 9; 27) after 12 months. Complete chimerism as well as best response was not achieved immediately post-transplant but took a median of 3 months to develop. The 2-year probability of relapse was 31% (95% CI 18; 44), with no event occurring later than 12 months post transplant in the absence of TCD. With one exception, relapses were not observed after onset of chronic graft-versus-host disease. Event-free and overall survival at 24 months were 56% (95% CI 43; 69) and 72% (95% CI 61; 83), respectively. The median follow-up was 18 (1-44) months. Donor lymphocyte infusions or secondary transplants were performed in 19 patients with insufficient disease control and/or incomplete donor chimerism post-transplant, leading to a response in seven patients (37%). Preliminary multivariate analysis identified less than PR at transplant (hazard ratio (HR) 3.5; Po0.01) and alternative donor (HR 3.1; P ¼ 0.02) as significant risk factors for relapse, whereas number of previous regimens 42 (HR 5.4; P ¼ 0.03), TBI (HR 2.5; P ¼ 0.05), and alternative donor (HR 2.3; P ¼ 0.08) were risk factors for survival. We conclude that RIC might favorably influence the outcome after allogeneic SCT for CLL by reducing TRM while preserving graft-versus leukemia activity.
Introduction
With a median survival of about 10 years, the natural course of B-cell chronic lymphocytic leukemia (CLL) is often indolent. 1 The prognosis is considerably worse, however, if advanced stage or adverse biological risk factors are present, such as high leukocyte count, short lymphocyte doubling time, unfavorable cytogenetics, or an unmutated status of the variable region of the immunoglobulin heavy chain gene. [1] [2] [3] [4] [5] To improve the dismal outlook of younger patients with poor-risk CLL, autologous and allogeneic stem cell transplantation (SCT) have been explored during recent years.
In contrast to auto-SCT, relatively few relapses occur after allogeneic transplantation, and the survival curves appear to approach a plateau in the long term, suggesting that graft-versus leukemia (GVL) effects are active in CLL. 6 Thus, allotransplantation may have curative potential in this disease. In spite of this, the overall survival (OS) after allogeneic SCT is reported to be only 45-60% at 3-4 years post-transplant because of the substantial toxicity associated with allografting for CLL using standard myeloablative regimens [7] [8] [9] [10] [11] (and Pavletic et al Proc ASCO 2000; 19:4a; abstract). A recent update of the European Group for Blood and Marrow Transplantation (EBMT) database comprising 209 allografted patients with CLL disclosed a 3-year treatment-related mortality (TRM) of 40%, which is clearly more than after standard indications such as acute leukemias or chronic myeloid leukemia (Michallet et al Blood 2001; 98:859a, abstract) . The causes of these discouraging results are not completely clear, but patient age, selection of poor-risk patients with extensive pretreatment, and the CLL-associated incompetence of the immune system may all have contributed to the high TRM observed.
Since the GVL effect appears to be very active in CLL, the intensity of the conditioning regimen may not be as important as initially believed. Provided that they are immunosuppressive enough to establish donor chimerism, less aggressive preparative treatments may be therefore suitable in this disease. Given this fact on the one hand and the extremely high TRM associated with standard myeloablative conditioning on the other, the use of nonmyelo-ablative, reduced-intensity conditioning (RIC) regimens is particularly appealing in CLL. During the past years, various strategies of reducing the preparative regimen's toxicity while preserving its immunosuppressive effect have been developed. Early studies of CLL patients in these preliminary series suggest that this approach can result in long-term remissions while avoiding excessive TRM 12, 13 (Schetelig et al Blood 2000; 96:200a, abstract; Dreger et al Bone Marrow Transplant 2001; 27:S37, abstract). The aim of this retrospective study was to confirm these initial impressions on a large patient number in order to provide a scientific basis for prospective clinical trials on RIC allografting for CLL.
Methods

Survey
This was a retrospective survey among centers belonging to the EBMT. In January 2001, all 150 EBMT centers known to undertake allogeneic transplants were asked if they had performed allogeneic SCT for CLL using dose-reduced conditioning. Those 40 centers with positive response received a second questionnaire asking for details. The second questionnaire included questions regarding patient and disease characteristics (age, sex, date of diagnosis, maximum Binet stage during the course of the disease, risk factors, pretreatment, fludarabine exposure, previous autotransplant, remission status at transplant, performance status at transplant, concomitant disease), graft/transplant characteristics (stem cell source, Tcell depletion (TCD), CD34+ cell number transfused, donor, date of SCT, conditioning regimen, graft-versus host-disease (GVHD) prophylaxis, peritransplant toxicity), and outcome (post-transplant toxicity, extent and kinetics of acute GVHD and chronic GVHD, maximum donor chimerism and time to maximum chimerism, response to transplant and time to best response, time to relapse or progression, disease status and survival at last follow-up, cause of death). Submitted questionnaires were checked for clinical plausibility. Missing information and data inconsistency were clarified by individual requests. Data were stored at the Leiden EBMT Data Centre for analysis.
In October 2001 and May 2002, follow-up questionnaires were sent out for each individual patient submitted asking for follow-up data on chronic GVHD, chimerism, best response, remission status, donor lymphocyte infusion (DLI), reason for DLI, response to DLI, and survival. Submission of additional patients was allowed at these occasions.
Minimum data required for inclusion of a patient in the analysis were diagnosis of CLL, age, time from diagnosis, prior treatment details, status at transplant, conditioning regimen, GVHD prophylaxis, TCD, date of transplant, date of follow-up, disease status at follow-up, date of disease progression/death, and cause of death.
Definitions
Histological diagnosis was based on local review. Evaluation of clinical remission was based on the criteria defined by the revised NCI guidelines.
14 'Nodular partial remissions' according to NCI were regarded as partial remissions for the purpose of this analysis. Relapse/progression required appearance of new lesions or increase of pre-existing manifestations by more than 50%. Patients included in the study received conditioning with regimens of an intensity equivalent to or less than that of BEAM+CAMPATH-1. Conditioning regimens were designated as 'moderate' and 'intensive', respectively, according to the probability of short-term autologous recovery in case of engraftment failure. Basically, regimens containing busulfan doses of 48 mg/kg or melphalan doses of 4110 mg/m 2 were defined as 'intensive', whereas all other regimens were considered as 'moderate'. 'TCD' was defined as treatment with ex vivo TCD or peritransplant in vivo treatment with any type of antithymocyte globuline (ATG) or with the monoclonal antibody CAMPATH-1. Severe toxicity was defined as toxicity of grade 3 or higher according to the National Cancer Institute Common Toxicity Criteria (http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf).
Statistical analysis
Survival time data were calculated from the time of transplant using Kaplan-Meier product-limit estimates. End points were defined as follows: OS was death from any cause. For calculation of event-free survival (EFS), clinical relapse, progression, and death from any cause were counted as events. Events relevant for the end point 'time to clinical progression or relapse' were clinical progression or disease recurrence. Events determining TRM were all deaths not because of CLL. Patients undergoing DLI or second SCT for relapse were censored for TRM but not for OS analysis. Chronic GVHD was defined as first occurrence of clinical signs of limited or extensive chronic GVHD.
Fisher's exact test was used to compare qualitative parameters, and Mann-Whitney tests were used to compare quantitative parameters between subgroups of patients. Survival times were compared by univariate log-rank testing using SPSS for Windows software (release 10.0; SPSS Inc., Chicago, IL, USA). For multivariate analyses, the Cox proportional hazards model was used. In the multivariate analyses, a backwards selection procedure was performed, starting with a limited number of a priori chosen variables. The choice was based both on clinical arguments and availability of sufficient data. For all multivariate models, an additional analysis was performed to assess a possible confounding effect of the removal of any patient from the multivariate model when at least one of the included risk factors has a missing value. Based on the final model, each risk factor is studied in turn by dichotimizing the other risk factors into two categories: 'valid' and 'missing'. Then the same model is fitted again (this time including all patients), adding the interaction of that risk factor with all other dichotomized ones. The interpretation of each of the interaction terms is an estimate of the possible confounding effect of the 'missingness' of the other factors on that particular risk factor. When such an effect is clinically significant, the conclusion can be drawn that substantial bias occurs in the estimate of the risk factor effect by being forced to estimate it on a subset of patients because of the need to adjust for the confounding effect of the other factors. Kaplan-Meier estimates were generated with GraphPad Prism software (release 3.02; San Diego, CA, USA). Data were analyzed as of June 15, 2002 .
Ethical committee approval
Ethical committee approval for this study was obtained at each center as required.
Results
Patients
Data on 79 patients treated with RIC for allografting for CLL between August 1998 and December 2001 were submitted. Two patients were excluded because of insufficient follow-up data, leaving 77 patients for analysis. Patient characteristics are presented in Table 1 . Almost all patients were in an advanced stage and more than 80% had at least one biological risk factor (lymphocyte count 450 Â 10 9 /l and/or lymphocyte doubling time (LDT) o12 months). Although the median time from diagnosis to transplant was almost 4 years and the median number of previous chemotherapy regimens was 3, the vast majority of patients (80%) had still an acceptable performance status. Only two-thirds of the cases, however, were in complete or partial remission at the time of transplant, whereas the remainder had uncontrolled or refractory disease. Most patients had been exposed to fludarabine prior to conditioning for allografting.
Conditioning regimens
Moderate conditioning regimens were mainly low-dose total body irradiation (TBI) or cyclophosphamide based and administered to 56% of the patients, whereas the remainder received more intense conditioning consisting of fludarabine-busulfan or high-dose melphalan combinations (see Table 2 for details). In 40% of the patients, in vivo TCD with ATG or CAMPATH-1H was part of the conditioning regimen.
Transplant characteristics
G-CSF-mobilized blood grafts were used in 91% of the patients, whereas the remainder received unmanipulated bone marrow.
Donors were usually HLA-identical siblings; unrelated HLAdonors were used in only 18% of the cases. A single patient received a graft from an HLA-mismatched related donor (Table 3) . With the exception of the three patients who received ex vivo TCD, cyclosporin A (CSA) with or without short-course methotrexate or mycophenolate mofetil was administered for additional prophylaxis of graft-versus-host disease (GVHD) in all cases. Post-transplant G-CSF was given to 47% of the patients.
Toxicity and GVHD
The median duration of severe neutropenia (o0.5 Â 10 9 /l) was 12 (0-28) days. Neutrophil recovery occurred in all cases. Parenteral nutrition was required by 24% of the patients. The median duration of hospital stay was 28 (8-86) days. Severe infections were reported in 37% of the patients, mostly in the context of acute or chronic GVHD. Other severe nonhematological toxicity comprised veno-occlusive disease, heart failure, renal failure, hemorrhage, hemolysis, and diabetic coma (Table 4) . Clinically relevant acute GVHD (grades II-IV) developed in 34% of the patients and was severe (grades III-IV) in 16%. The risk estimate of limited or extensive chronic GVHD at 1 year was 58% (95% confidence interval (95% CI) 45; 70) among 71 patients evaluable. In all, 12 patients succumbed to infections, complications of GVHD or other toxicity, translating into an estimated risk of TRM of 18% (95% CI 9; 27) at 1 year with 51 individuals still at risk at 12 months post-transplant ( Figure 1 ).
Chimerism
At least transient partial or complete (495%) hematopoietic donor chimerism was observed in all but two of 73 patients evaluable for this end point (including the results of DLI). However, chimerism development was much slower than after myeloablative conditioning: the probability of being a complete chimera was only 32% (95% CI 22; 42) at 1 month, 64% (95% CI 53; 75) at 3 months, and 87% (95% CI 81; 95) at 12 months post-transplant, reflecting the immune-mediated establishment of donor hematopoiesis after this kind of procedure ( Figure 2 ). More intense regimens as defined above tended to result in faster achievement of complete chimerism in comparison with more moderate regimens (79 vs 54% at 3 months, P ¼ 0.04). Table 2 Conditioning regimens Reduced intensity conditioning for allo-SCT in CLL P Dreger et al
Responses and outcome
A complete (n ¼ 53; 69%) or partial (n ¼ 17; 22%) remission was reported in 70 patients (91%), whereas the remainder had stable or progressive disease after SCT. In parallel with chimerism, the best response was not achieved immediately post-transplant but took a median of 3 (0.5-12) months to develop (Figure 2) . Chronic GVHD had a major impact on the probability of achieving a complete response (CR): All but one of the patients who developed chronic GVHD at any time reached CR, whereas CR was achieved in only 14 of 33 evaluable patients (42%), who never had chronic GVHD (Po0.0001; Fisher's exact test). Accordingly, among 37 evaluable patients only a single relapse was reported after onset of chronic GVHD, while 19 relapses occurred in the absence of chronic GVHD (Po0.0001). Altogether, relapse or progression was observed in 20 patients after a median time of 4 (1-30) months, translating into a 2-year probability of progression or relapse of 31% (95% CI 18; 44), whereas EFS and OS were 56% (95% CI 43; 69) and 72% (95% CI 61; 83) at 2 years, respectively ( Figure 3 ). The median follow-up was 18 (1-44) months.
Prognostic factors for outcome
Using univariate log-rank analyses, only less than PR at transplant (hazard ratio (HR) 3.8; Po0.01), nonsibling donor (HR 3.5; Po0.01), and acute GVHD II-IV (HR 0.24; P ¼ 0.04) had a significant predictive value for relapse, whereas age 450, LDT o12 months, ECOG status, time from diagnosis 43 years, time from diagnosis 44 years, number of pretreatment regimens, source of stem cells (PBSC vs BM), TCD, extent of chimerism, conditioning regimen intensity, TBI, and previous fludarabine had no effect. Negative predictors for OS were more than two lines of chemotherapy prior to transplant (HR 6.4; Po0.01), less than PR at transplant (HR 2.7; P ¼ 0.02), nonsibling donor (HR 3.0; P ¼ 0.01), acute GVHD (HR 2.5; P ¼ 0.03), and, interestingly, the use of TBI conditioning (HR Months from transplant Percent with TRM Figure 1 Treatment-related mortality. Reduced intensity conditioning for allo-SCT in CLL P Dreger et al 2.9; P ¼ 0.01). Owing to the low number of events, only a limited number of explanatory variables could be included into multivariate analysis. These were donor, status at transplant, and TCD for relapse and number of previous regimens, donor, status at transplant, and TBI for OS. The final models contained less than PR at transplant (HR 3.5) and nonsibling donor (HR 3.1) as significant risk factors for relapse; and number of previous regimens 42 (HR 5.4), TBI (HR 2.5), and alternative donor (HR 2.3) as risk factors for survival although the latter two were only of borderline significance (Table 5) .
Outcome differentiated for TCD
Since TCD might obscure possible GVL effects after RIC in CLL, we studied the outcome in the absence of TCD. The cohort that did not receive TCD was similar to that with TCD in terms of age, stage distribution, time from diagnosis, previous chemotherapy regimens, and status at SCT, but differed with regard to LDT, fludarabine exposure, donor type, and conditioning regimen intensity (Table 6 ). Although the overall incidence of relapse or progression was not significantly reduced without TCD, not a single relapse was observed after 12 months posttransplant in the non-TCD group, translating into a plateau in the incidence curve (P 0.018; log-rank comparison conditional on being alive and relapse free at 12 months; 2-year relapse risk 22% [95% CI 9; 35]) ( Figure 4 ). In the TCD patients, a plateau was not visible with the present follow-up. TCD had no influence on TRM and overall outcome.
Donor lymphocyte infusions
Donor cell infusions were commenced in 19 of 68 patients (28%) with information available at a median of 6 (2-19) months post-transplant. Donor cells consisted of unmobilized peripheral blood mononuclear cells (n ¼ 16) or mobilized PBSC (n ¼ 3). Reasons for DLI were insufficient disease control (n ¼ 10), incomplete donor chimerism (n ¼ 7), or both (n ¼ 2).
A preference for the previous use of a particular conditioning regimen or TCD was not evident in the 19 patients receiving DLI. With a median follow-up of 8 months, responses to DLI were observed in seven patients (37%). Responses were all durable and consisted in CR (n ¼ 3) or PR (n ¼ 1) in those who were treated for resistant disease, and in achievement of complete (n ¼ 2) or improvement of chimerism (n ¼ 1) in those individuals who were treated for incomplete chimerism, respectively. The three patients receiving mobilized PBSC all died because of treatment-related complications, whereas no patient with unmobilized DLI succumbed to toxic death.
Discussion
In CLL, the much lower incidence of relapse after allogeneic in comparison with autologous transplantation as well as the Not considered in the analysis. 98:482a, abstract). On the other hand, the main reason for the unsatisfying results of allotransplantation in CLL is the extremely high TRM associated with standard myeloablative conditioning. Thus, the purpose of the present study was to collect some evidence that RIC can improve the outcome after allogeneic SCT for CLL by reducing TRM while maintaining GVL activity.
The 18% 1-year TRM estimate (only 5% after 3 months) observed in the present series is in accordance with published experience with RIC for lymphoid malignancies, 20, 21 but compares favorably with the corresponding figures seen in similar analyses of patients who received standard myeloablative conditioning: the retrospective registry studies of the EBMT (Michallet et al Blood 2001; 98:859a, abstract) and the International Project on CLL transplants (Esteve et al Blood 2001; 98:482a, abstract) both showed a 1-year TRM of 30% or higher. Patient risk profiles (time from diagnosis, pretreatment, performance status, etc) in these series were comparable to ours, and the median age was about 10 years less. However, only prospective studies can demonstrate whether there is actually a comparably lower mortality and whether this is because of the use of RIC or other improvements in supportive therapy that have emerged during recent years.
As the incidences of acute and chronic GVHD were not substantially different, the reduced mortality after RIC seems to be largely because of a decrease of infectious deaths. This might be explained by less severe damage of host defense mechanisms after RIC, such as the neutrophil system and the mucosal barrier. The use of RIC may delay rather than reduce the occurrence of treatment-associated complications. Since no TRM event occurred beyond 1 year post-transplant, with 51 patients at risk left, our follow-up appears to be long enough to exclude a significant bias by such effects. Another possible explanation for the low incidence of TRM in our series might be the large fraction of patients who received ex vivo ATG or CAMPATH-1, but a measurable influence of TCD on TRM in the setting of RIC does not emerge from this or other series. 22 There are four lines of evidence suggesting that GVL mechanisms have been effective in the patients analyzed here: the first is the large proportion of patients who achieved their best response later than 3 months post-transplant. These kinetics can hardly be attributed to the effects of the conditioning regimen alone. The second consists of the fact that in patients who had not undergone TCD there was no relapse beyond the first year post-transplant. Since the conditioning regimens administered here are not believed to be curative for CLL, this suggests that residual leukemic cells surviving the conditioning regimen and being responsible for the continuous pattern of relapse observed after autologous SCT are controlled by immunologic mechanisms after allografting with RIC in the long term. Overall, the 2-year relapse incidence was 22% 9,35 in the non-TCD patients, which is within the range of registry data reported for full conditioning for CLL ( . Third, chronic GVHD almost completely prevented the development of relapses. Finally, the observation of responses to DLI is clearcut evidence for the fact that GVL effects can be established in the context of RIC. Taken together, GVL activity as the main therapeutic principle in allogeneic SCT for CLL appears to be effective also with RIC. Whether this will translate into disease control comparable to that achieved with myeloablative allo-SCT remains to be proven by prospective studies.
What is the optimum regimen for RIC? Generally, two basic strategies can be identified: the first uses moderate conditioning with low-dose TBI and/or clearly nonmyeloablative combinations of purine analogues with alkylating agents without TCD. 12, 20, 21, 23 The other is characterized by in vivo TCD using ATG or CAMPATH-1 combined with more intensive conditioning with melphalan or busulfan doses that may prevent shortterm autologous recovery. [24] [25] [26] In spite of some treatment heterogeneity, the vast majority of our patients can be assigned to one of these two groups. As observed elsewhere, 22 in this 
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Figure 4
Time to progression or relapse of patients without (solid line) and with TCD (broken line).
Reduced intensity conditioning for allo-SCT in CLL P Dreger et al series, the TCD approach was associated with much less chronic GVHD but more late relapses. However, a higher risk of relapse caused by TCD, if confirmed by prospective studies, might be compensated by the preemptive use of DLI. This might explain that in the present series the overall outcome did not differ between the TCD and non-TCD groups. Accordingly, in CLL, both strategies of RIC are clearly worth being studied in prospective trials. Particular features of CAMPATH-1 in comparison to ATG in this context are its stronger TCD capacity and its intrinsic anti-CLL activity.
The results of the Cox analysis for prognostic factors must be regarded as very preliminary because of the low number of events as well as the limited number of explanatory variables included. For instance, the higher relapse risk observed with nonsibling donors strongly suggests that the decision to proceed to transplant without a sibling donor is prompted by unfavorable patient conditions that are not reflected by the variables analyzed here. Other significant predictors of an unfavorable outcome by multivariate analysis were nonremission at transplant and intensive pretreatment. These observations are not surprising and suggest that RIC allografting might be considered before the malignant clone has acquired chemotherapy resistance and before too much treatment-associated toxicity has accumulated. A prerequisite for performing RIC allo-SCT earlier in the course of the disease, however, is an appropriate assessment of genetic risk factors to identify those individuals who will do very poorly under conventional treatment or autografting. [3] [4] [5] 27, 28 In both univariate and multivariate analyses, patients prepared with TBI-containing regimens had a significantly increased risk of dying. A possible explanation could be the stronger CLL-specific activity conferred with the fludarabinecontaining regimens. However, again, one has to bear in mind the limited power of our prognostic factor analysis, implying that confounding factors might exist in addition to those considered here which are responsible for the adverse TBI effect.
In conclusion, in patients with CLL, RIC promises to reduce TRM substantially while maintaining the GVL-mediated curative potential of allogeneic transplantation. The optimum strategy of RIC and in particular the role of TCD remain to be determined. These findings warrant prospective studies aiming at evaluation of RIC allografting in younger patients with poor-risk CLL.
EBMT participating institutions
